Bile salt binding properties of commonly used gastrointestinal drugs: maalox, carafate, and questran

The effect of sucralfate on serum lipids and lipoproteins in normal volunteers [corrected]

Sucralfate is used in the treatment and prophylaxis of peptic ulcer disease. One possible mechanism of action is the binding of bile acids. Because the absorption of dietary fat and cholesterol is dependent on the presence of bile acids in the small intestines, sucralfate therapy may produce changes in serum lipoprotein composition qualitatively similar to bile acid sequestrants, such as cholestyramine, which reduce serum cholesterol levels. Although changes in total serum cholesterol have not been reported in sucralfate efficacy studies, the effect of sucralfate on serum lipoprotein composition has not been specifically addressed. The purpose of this study was to prospectively examine the effect of sucralfate on serum lipids and lipoproteins in normal volunteers. Eight healthy volunteers (six men, two women) were recruited for this 10-week study. Drugs known to affect cholesterol levels were not permitted before or during the study. Diet composition during the study period was unaltered from before the study. Subjects took 1 g sucralfate orally 1 hour before meals and at bedtime (four times a day) for 8 weeks, followed by a 2-week washout period. Fasting blood samples were obtained at baseline and weekly, and were analyzed for serum total and HDL cholesterol and for triglycerides. Levels of LDL cholesterol were estimated. After eight weeks of sucralfate, HDL cholesterol increased from baseline by 2.5 mg/dL (6.6%, from 37.6 +/- 9.5 to 40.1 +/- 8.69 mg/dL), and LDL cholesterol decreased by 7.6 mg/dL (6.4%, from 134 +/- 28.1 to 125.4 +/- 34.1). Total cholesterol decreased by 3.5 mg/dL (1.8%, from 192.9 +/- 34.3 to 189.4 +/- 37.2 mg/dL.(ABSTRACT TRUNCATED AT 250 WORDS)

Dietary protein source (soybean vs. casein) and taurine status affect kinetics of the enterohepatic circulation of taurocholic acid in cats

The effect of dietary protein source (soybean vs. casein) and taurine status on kinetics of [24-14C] and [taurine-2-3H]taurocholic acid was determined by isotope dilution in 10 adult male cats (six taurine-replete and four taurine-depleted). Taurine-replete cats were fed 1500 mg taurine/kg purified diets containing either 435 g/kg casein (1500 Cas) or soybean protein (1500 Soy) in a crossover design. Taurine-depleted cats were fed the soybean protein diet with no taurine (0 Soy). Specific activity of [14C]- and [3H]taurocholic acid in bile was determined for 6 d following a pulse dose of dual-labeled taurocholic acid. Taurocholic acid pool size was significantly greater in cats when fed the 1500 Soy diet than when fed the 1500 Cas or than in cats fed the 0 Soy diet. Total entry rate, irreversible loss rate and recycling rate of [taurine-2-3H]taurocholic acid and the irreversible loss rate of [24-14C]taurocholic acid tended to be greater in cats when fed the 1500 Soy than the 1500 Cas diet. Irreversible loss rates of taurocholic acid in taurine-replete cats fed the 1500 Soy diet were significantly greater than in taurine-depleted cats, 356 vs. 120 mumol/d [24-14C]taurocholic acid and 445 vs. 56 mumol/d [taurine-2-3H]taurocholic acid. The fraction of taurocholic acid was greater, and the fraction of taurochenodeoxycholic and taurodeoxycholic acids lower in cats when fed the 1500 Soy than when fed the 1500 Cas diet. Taurine-depleted cats had less taurocholic, taurochenodeoxycholic, and taurodeoxycholic acids and greater glycocholic and cholic acids than taurine-replete cats fed the 1500 Soy diet. This study demonstrates that both dietary protein source and taurine status affect taurocholic acid kinetics and bile acid composition in cats.